Brad Loncar discusses the rallies in both Moderna and Regeneron following their quarterly results. Moderna's earnings and revenue blew past expectation, despite the company warning of declining profit as a result of unused Covid-19 vaccines. Regeneron also beat on top and bottom line, amid record sales of several of its products. Tom White then breaks down a bullish example trade in Moderna and a neutral to bullish trade in Regeneron.